# Octreotide in Severe Polycystic Liver Disease

> **NCT00426153** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 42 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant
- Polycystic Liver Disease
- Hepatomegaly
- Liver Diseases
- Kidney, Polycystic
- Abdominal Pain

## Interventions

- **DRUG:** Octreotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00426153
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2012-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426153, "Octreotide in Severe Polycystic Liver Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00426153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*